HALO - Halozyme Therapeutics - Stock & Dividends

Halozyme Therapeutics Inc. is a biopharma technology platform company that develops and commercializes innovative enzymes and devices to improve the delivery of injectable biologics and other therapeutic molecules. The company's products are built around its patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the efficient delivery of medications through subcutaneous injection, a more convenient and patient-friendly approach.

The company's portfolio includes a range of products that leverage its proprietary enzyme technology. For instance, Hylenex recombinant is used to facilitate subcutaneous fluid administration, enhancing the dispersion and absorption of other injected drugs. The company also offers a range of products for the treatment of various diseases, including HIV, multiple sclerosis, breast cancer, and primary immunodeficiency disorders.

In addition, Halozyme Therapeutics has partnered with other pharmaceutical companies to develop and commercialize products that utilize its enzyme technology. For example, the company has collaborated with Genentech to develop Herceptin Hylecta, a subcutaneous injection for the treatment of breast cancer. Similarly, it has partnered with Janssen Biotech to develop DARZALEX, a medication for patients with amyloidosis, smoldering myeloma, and multiple myeloma.

The company's research and development pipeline is focused on expanding its enzyme technology into new therapeutic areas, including oncology, autoimmune diseases, and rare genetic disorders. With a strong track record of innovation and collaboration, Halozyme Therapeutics is well-positioned to continue making a significant impact in the biopharma industry.

Headquartered in San Diego, California, Halozyme Therapeutics was founded in 1998 and has established a global presence with operations in the United States, Switzerland, Belgium, Japan, and other countries. The company's commitment to improving patient outcomes and advancing medical research has earned it a reputation as a leader in the biopharma technology platform space.